Cargando…

MiR-335 promotes corneal neovascularization by Targeting EGFR

BACKGROUND: Corneal neovascularization (CRNV) is a severe threat to the vision of people. MicroRNA-335 (miR-335) has the function of facilitating angiogenesis. However, whether miR-335 regulates the progression of CRNV remains unclear. METHODS: The miR-335 expressions in CRNV rats induced by corneal...

Descripción completa

Detalles Bibliográficos
Autores principales: Qian, Jingjing, Yu, Junbo, Zhu, Xi, Liang, Shu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9199176/
https://www.ncbi.nlm.nih.gov/pubmed/35701740
http://dx.doi.org/10.1186/s12886-022-02481-0
Descripción
Sumario:BACKGROUND: Corneal neovascularization (CRNV) is a severe threat to the vision of people. MicroRNA-335 (miR-335) has the function of facilitating angiogenesis. However, whether miR-335 regulates the progression of CRNV remains unclear. METHODS: The miR-335 expressions in CRNV rats induced by corneal suture and HUVECs induced by b-FGF were detected by quantitative real-time PCR. For the miR-335 function, wound healing and tube formation assays were performed. For the miR-335 mechanism, a dual-luciferase reporter gene assay was conducted. Besides, for the epidermal growth factor receptor (EGFR) function, Cell Counting Kit-8 and wound healing assays were performed. Meanwhile, the rescue assay was used to assess the miR-335/EGFR function in the migration and angiogenesis of b-FGF-treated HUVECs. RESULTS: Functionally, the miR-335 knockdown weakened the migration and angiogenesis of b-FGF-treated HUVECs, while the miR-335 overexpression showed an opposite trend. Mechanistically, miR-335 interacted with EGFR and negatively regulated the expression of EGFR. The rescue assay illustrated that miR-335 regulated the migration and angiogenesis of b-FGF-treated HUVECs through EGFR. CONCLUSIONS: In general, our data confirmed that miR-335 facilitated the process of CRNV by targeting EGFR. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12886-022-02481-0.